The inherited KRAS-variant as a biomarker of cetuximab response in NSCLC

Authors

Joanne B Weidhaas, University of California, Los Angeles
Clifford G Robinson, Washington University School of Medicine in St. Louis
et al.

Journal

Cancer Research Communications

Publication Date

10-11-2023

Volume

3

Issue

10

First Page

2074

Last Page

2081

Document Type

Open Access Publication

DOI

10.1158/2767-9764.CRC-23-0084

Rights and Permissions

Weidhaas JB, Hu C, Komaki R, Masters GA, Blumenschein GR, Chang JY, Lu B, Dicker AP, Bogart JA, Garces YI, Narayan S, Robinson CG, Kavadi VS, Greenberger JS, Koprowski CD, Welsh J, Gore EM, MacRae RM, Paulus R, Bradley JD. The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC. Cancer Res Commun. 2023 Oct 11;3(10):2074-2081. doi: 10.1158/2767-9764.CRC-23-0084. © 2023 The Authors; Published by the American Association for Cancer Research This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.

Recommended Citation

Weidhaas, Joanne B; Robinson, Clifford G; and et al., "The inherited KRAS-variant as a biomarker of cetuximab response in NSCLC." Cancer Research Communications. 3, 10. 2074 - 2081. (2023).
https://digitalcommons.wustl.edu/oa_4/3148

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.